In the fiercely competitive GLP-1R agonist field, a weight loss effect of less than 15% to 20% will undoubtedly make the drug's market prospects more uncertain
Glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s, are becoming increasingly widespread, with the most notable examples including Ozempic, Wegovy, and Saxenda
Bioavailability is critical
Despite the high prevalence of CUD and its negative consequences, there are currently no FDA-approved medications
[DOI] [PubMed] [Google Scholar] 172.Rais R., Janak A., Tenora L., Nedelcovych M., Alt J., Englert J., Rojas C., Le A., Elgogary A., Tan J., et al
These inflammatory mediators cause the intense pelvic pain, adhesion formation, and tissue damage characteristic of the condition